Work at Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has led to the identification of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
CNCCS SCARL Collezione Nazionale Dei Composti Chimici E Centro Screening and IRBM SpA have prepared new serine protease NS3/non-structural protein 2B (NS3/NS2B) (dengue virus) and/or (West Nile virus) and/or (Zika virus) and/or Japanese encephalitis virus inhibitors.
Impact Therapeutics Inc. has disclosed new heteroaromatic and heterobicyclic compounds acting as Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Heterocyclic compounds acting as potassium channel subfamily T member 1 (KCNT1) and KCNT1 mutant inhibitors have been reported in a Actio Biosciences Inc. patent as potentially useful for the treatment of neurological disorders.
Therapies against aggressive T-cell lymphomas (TCLs) are limited and treatment resistance to histone deacetylase (HDAC) inhibitors often occurs. Polycomb protein EED is a key member of the polycomb repressive complex 2 (PRC2) complex and is an attractive therapeutic target for TCLs. APG-5918 is an EED inhibitor from Ascentage Pharma Group International Co. Ltd. that has been proven to disrupt the PRC2 functioning and has been tested in preclinical TCL models as a promising approach.
A global consortium led by Adaptvac ApS aims to design and test a new vaccine that could offer broad protection against several filoviruses, including Zaire ebolavirus, Sudan ebolavirus and Marburg virus.
At the 2025 Annual Congress of the European Association for Cancer Research (EACR), researchers from Cardiff University and collaborators presented their research on the role of BCL3 in tumor progression and the therapeutic potential of TNAT-101.
Archeus Technologies Inc. has obtained IND clearance from the FDA for ART-101, a novel receptor-based targeting small molecule for the imaging and treatment of prostate cancer.
Harbour Biomed Ltd. has established a global strategic collaboration with Otsuka Pharmaceutical Co. Ltd. to advance BCMAxCD3 bispecific T-cell engagers for the treatment of autoimmune diseases.
Aptevo Therapeutics Inc. has added a preclinical candidate, APVO-455, to its portfolio of CD3-directed candidates built on the CRIS-7-derived CD3 binding domain.
RSS
